[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

June 2019 - April 2015

Decade

Year

Issue

July 2017, Vol 3, No. 7, Pages 875-1007

Original Investigation

Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2017;3(7):906-912. doi:10.1001/jamaoncol.2016.6316

This randomized clinical trial examines whether zoledronic acid every 12 weeks was noninferior to zoledronic acid every 4 weeks in patients with metastatic breast cancer involving bone who had previously received a standard dosing regimen of zoledronic acid and/or pamidronate.

Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2017;3(7):913-920. doi:10.1001/jamaoncol.2016.4419

This randomized clinical trial evaluates the safety and efficacy of adjuvant girentuximab on disease-free survival and overall survival in patients with localized completely resected high-risk clear cell renal cell carcinoma.

Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by Fusobacterium nucleatum in Tumor Tissue

Abstract Full Text
free access
JAMA Oncol. 2017;3(7):921-927. doi:10.1001/jamaoncol.2016.6374

This population-based cross-sectional study uses data from the Nurses’ Health Study and Health Professionals Follow-up Study to examine the incidence of Fusobacterium nucleatum in tumor tissue in association with different dietary patterns in patients with colorectal cancer.

Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States

Abstract Full Text
free access
JAMA Oncol. 2017;3(7):928-935. doi:10.1001/jamaoncol.2016.6380

This cohort study investigates temporal patterns and factors associated with the receipt of adjuvant endocrine therapy in women with breast cancer in the National Cancer Database.

Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia

Abstract Full Text
free access
JAMA Oncol. 2017;3(7):936-943. doi:10.1001/jamaoncol.2016.6435

This case-control study assesses the association of cytotoxic, anti-inflammatory, and immunomodulating agents with the risk for developing myeloid neoplasms among patients with autoimmune disease.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033

Abstract Full Text
free access
JAMA Oncol. 2017;3(7):944-952. doi:10.1001/jamaoncol.2016.6728

This follow-up of a randomized clinical trial evaluates long-term survival in patients with gastrointestinal stromal tumors who were treated with 1 of 2 dose levels of imatinib mesylate and presents new molecular data regarding treatment outcomes.

Effect of Radiotherapy on Painful Bone Metastases: A Secondary Analysis of the NCIC Clinical Trials Group Symptom Control Trial SC.23

Abstract Full Text
free access
JAMA Oncol. 2017;3(7):953-959. doi:10.1001/jamaoncol.2016.6770

This secondary analysis of a National Cancer Institute of Canada trial investigates quality of life at days 10 and 42 after radiotherapy with a bone metastases–specific quality-of-life tool.

Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis

Abstract Full Text
free access
JAMA Oncol. 2017;3(7):961-968. doi:10.1001/jamaoncol.2016.6914

This meta-analysis establishes weighted effect sizes to compare exercise, psychological, combined exercise and psychological, and pharmaceutical interventions to treat cancer-related fatigue among patients with cancer during and after therapy.

FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis

Abstract Full Text
free access online only
JAMA Oncol. 2017;3(7):e170278. doi:10.1001/jamaoncol.2017.0278

This systematic review and pooled analysis assesses the efficacy of FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer.

Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis

Abstract Full Text
free access online only
JAMA Oncol. 2017;3(7):e170580. doi:10.1001/jamaoncol.2017.0580

This meta-analysis examines the association of minimal residual disease status with acute lymphoblastic leukemia in children and adults.

Brief Report

Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2017;3(7):969-973. doi:10.1001/jamaoncol.2016.6007

This phase 2, single-arm clinical trial examines the safety and objective response rate of topical imiquimod in combination with systemic chemotherapy for treatment of breast cancer cutaneous metastases.

Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy

Abstract Full Text
free access
JAMA Oncol. 2017;3(7):974-978. doi:10.1001/jamaoncol.2017.0115

This study compares the local tumor immune microenvironment in anal squamous cell carcinomas from HIV-positive and HIV-negative patients.

Research Letter

Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology

Abstract Full Text
free access
JAMA Oncol. 2017;3(7):996-998. doi:10.1001/jamaoncol.2016.4983

This study compares reports from 2 next-generation sequencing tests to determine the level of concordance between platforms.

Odontoma in a 255-Million-Year-Old Mammalian Forebear

Abstract Full Text
free access
JAMA Oncol. 2017;3(7):998-1000. doi:10.1001/jamaoncol.2016.5417

This study describes cancer in a 255-million-year-old mammalian forebear and comments on the implications for establishing the phylogenetic and physiologic conditions under which such pathologic conditions first arose.

Review

Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review

Abstract Full Text
has active quiz
JAMA Oncol. 2017;3(7):980-988. doi:10.1001/jamaoncol.2016.3350

This review examines the incidence, clinical presentations, and mechanisms of cardiovascular complications in patients with multiple myeloma.

JAMA Oncology Diagnostic Test Interpretation

FLT3 Mutation Testing in Acute Myeloid Leukemia

Abstract Full Text
has active quiz
JAMA Oncol. 2017;3(7):991-992. doi:10.1001/jamaoncol.2017.0257

This Diagnostic Test Interpretation examines FLT3 mutation testing in acute myeloid leukemia.

Viewpoint

Evidence in Favor of Standard Surgical Treatment for Rectal Cancer

Abstract Full Text
JAMA Oncol. 2017;3(7):885-886. doi:10.1001/jamaoncol.2016.5397

This Viewpoint argues that that it is premature to practice selective withdrawal of surgery based on the curative contribution of surgery, the lack of reliable predictive biomarkers, and the scarcity of solid evidence in support of this practice.

Surgery for Patients With Rectal Cancer—Time to Listen to the Patients and Recognize Reality

Abstract Full Text
JAMA Oncol. 2017;3(7):887-888. doi:10.1001/jamaoncol.2016.5380

This Viewpoint argues that surgery is not necessary for all patients with rectal cancer who respond to chemoradiation.

Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World

Abstract Full Text
JAMA Oncol. 2017;3(7):889-890. doi:10.1001/jamaoncol.2016.5296

This Viewpoint discusses overall survival in cancer trials as a surrogate end point for real-world patients.

From the JAMA Network

An Important Step Forward for Biosimilars in Cancer Treatment

Abstract Full Text
JAMA Oncol. 2017;3(7):989-990. doi:10.1001/jamaoncol.2016.6789

This commentary discusses the findings of a randomized clinical trial of trastuzumab vs a biosimilar in patients with metastatic breast cancer that was published in JAMA and posits 3 questions for consideration moving forward in the development and clinical use of biosimilars.

Editorial

Less Intense Dosing Schedule for a Bone-Modifying Agent

Abstract Full Text
JAMA Oncol. 2017;3(7):893-894. doi:10.1001/jamaoncol.2016.6240

Perioperative Management of Localized Kidney Cancer: Watching and Waiting

Abstract Full Text
JAMA Oncol. 2017;3(7):895-896. doi:10.1001/jamaoncol.2016.4409
Editor's Note

Single-Fraction Radiotherapy and Early Subjective Improvement in Pain

Abstract Full Text
free access
JAMA Oncol. 2017;3(7):960. doi:10.1001/jamaoncol.2016.6723
JAMA Oncology Patient Page

Cancer-Related Anxiety

Abstract Full Text
free access
JAMA Oncol. 2017;3(7):1007. doi:10.1001/jamaoncol.2017.0254
Cancer Care Chronicles

When “Actionable” Genomic Sequencing Results Cannot Be Acted Upon

Abstract Full Text
JAMA Oncol. 2017;3(7):891-892. doi:10.1001/jamaoncol.2016.3283
Comment & Response

Androgen Deprivation Therapy and Subsequent Dementia

Abstract Full Text
JAMA Oncol. 2017;3(7):1000-1001. doi:10.1001/jamaoncol.2016.5854

Tumor Sidedness and Prognosis in Colorectal Cancer: Is Microbiome the Missing Link?

Abstract Full Text
JAMA Oncol. 2017;3(7):1000. doi:10.1001/jamaoncol.2017.0034

Androgen Deprivation Therapy and Subsequent Dementia—Reply

Abstract Full Text
JAMA Oncol. 2017;3(7):1001-1002. doi:10.1001/jamaoncol.2017.0405

Androgen Deprivation Therapy and Subsequent Dementia

Abstract Full Text
JAMA Oncol. 2017;3(7):1001. doi:10.1001/jamaoncol.2017.0509
Correction

Missing Author Initial in Byline

Abstract Full Text
free access
JAMA Oncol. 2017;3(7):1002. doi:10.1001/jamaoncol.2017.0705
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2017;3(7):879. doi:10.1001/jamaoncol.2016.4446
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2017;3(7):875. doi:10.1001/jamaoncol.2016.4445
×